Skip to content
Home/Companies/Biotech/Anciata Therapeutics, Inc.

Anciata Therapeutics, Inc.

Biotech·United States·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns Anciata Therapeutics, Inc.?

Anciata Therapeutics, Inc. is currently owned by TVM Capital Life Science through TVM Life Science Innovation (2016 vintage), since 2025.

Hand-verified · updated 2026-08-11

TVM Capital Life Science
Investor
TVM Capital Life Science
TVM Life Science Innovation · 2016 · VC

Key facts

HQUnited States
SectorBiotech
StatusActive

More from TVM Life Science Innovation

Other portfolio companies in the same fund.

LAmAb Biologics, Inc.
Active
BiotechUnited States· 2023
Mage Biologics, Inc.
Active
BiotechUnited States· 2023
Recurv Pharma, Inc.
Active
BiotechUnited States· 2023
Auricula Biosciences
Active
BiotechUnited States· 2022
Immunorx Pharma, Inc.
Active
BiotechUnited States· 2021
Kent Imaging, Inc.
Kent Imaging, Inc.
Active
MedTechCanada· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Anciata Therapeutics, Inc.

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Anciata Therapeutics, Inc..

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue